论文部分内容阅读
用ＤＣＣ方法检测了５５例卵巢恶性肿瘤及１２例良性肿瘤胞浆雌激素受体（ＥＲ），其中３４例还同时测定了孕激素受体（ＰｇＲ）。结果表明，卵巢恶性肿瘤中４１．８％ＥＲ阳性，４１．２％ＰｇＲ阳性，明显高于良性肿瘤，后者ＥＲ为８．３％，ＰｇＲ为２０．０％。卵巢恶性肿瘤中的ＥＲ、ＰｇＲ与某些临床、病理因素有一定关系。性索间质肿瘤的ＥＲ含量最高（１２６．６ｆｍｏｌｅ／ｍｇ），生殖细胞瘤最低（５．３ｆｍｏｌｅ／ｍｇ）。ＰｇＲ则在性索间质肿瘤及上皮性病中较高（分别为４９．８ｆｍｏｌｅ／ｍｇ及４８．６ｆｍｏｌｅ／ｍｇ）。ＥＲ有随肿瘤组织学分级增高而下降的趋势，ＰｇＲ则无明显规律。两种受体在临床早期组均高于晚期组。经过长期随访发现，ＥＲ、ＰｇＲ阳性患者的５年存活率及平均生存时间均比阴性患者高。本研究初步表明，卵巢恶性肿瘤中亦有部分为性激素依赖性肿瘤，且受体的状态与肿瘤的分化程度及患者的预后有一定关系，这就为卵巢癌的内分泌治疗及对预后的估价奠定了一定的理论基础。
55 cases of ovarian cancer and 12 cases of benign tumor cytoplasmic estrogen receptor (ER) were detected by DCC method, of which 34 cases also measured the progesterone receptor (PgR). The results showed that 41.8% of ER positive ovarian cancer, 41.2% PgR positive was significantly higher than benign tumors, the latter ER 8.3%, PgR 20.0%. Ovarian cancer in the ER, PgR and some clinical, pathological factors have a certain relationship. Sex stromal tumors have the highest ER content (126.6 fmole / mg) and the lowest germ cell tumor (5.3 fmole / mg). PgR was higher in stromal tumors of the sex cord and epithelial disease (49.8 fmole / mg and 48.6 fmole / mg, respectively). ER with tumor histological grade increased and decreased trend, PgR no obvious rules. Both receptors were higher in the early clinical group than in the late group. After long-term follow-up found that ER, PgR-positive patients 5-year survival rate and mean survival time were higher than negative patients. The preliminary study shows that ovarian cancer is also part of sex hormone-dependent tumors, and the receptor status and tumor differentiation and prognosis of patients have a certain relationship, which for the endocrine treatment of ovarian cancer and the prognosis of the valuation laid A certain theoretical basis.